GMP Support Supervisor

Job description:

We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you.

We are currently recruiting for a GMP Support Supervisor to join the Manufacturing Support team.

The purpose of this role is to lead a team of GMP Support Assistants, coordinating the team’s day-to-day support activities, in order to maintain process continuity and achieve the production schedule whilst maintaining GMP, safety and environmental compliance.

OXB’s Manufacturing Team is responsible for the production and aseptic fill and finish of vectors, for our clients and partners, to Good Manufacturing Practice (GMP) standard.

Your responsibilities in this role would be:

• Taking accountability and line managing a team of GMP Support Assistants.


• Co-ordinating and contributing to daily cleaning, waste disposal and material transfer activities including stock check and organisation.


• Ensuring that all work within the manufacturing facility is carried out in compliance with the facilities GMP procedures.


• Becoming a Subject Matter Expert (SME) for facility SOP's.


• Contributing to quality documentation for the supporting manufacturing areas.


• Contributing to improvement projects.


• Performing all work within the manufacturing facility in compliance with the facilities health and safety and GMP procedures.

We are looking for:

• A-Levels, and/or previous industrial experience, preferably within a GMP environment.


• Strong organisational and people management skills.


• Ability to communicate on all levels.


• Good problem-solving skills with the ability to make informed decisions.


• Excellent verbal and written communication skills, with a strong knowledge of MS Office applications.

About Us:

OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages


• Wellbeing programmes


• Development opportunities


• Welcoming, friendly, supportive colleagues


• A diverse and inclusive working environment


• Our values are: Responsible, Responsive, Resilient, Respect


• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.